Study confirms disparities in triple-negative breast cancer diagnoses

(Wiley) A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, shows that women of color and young women may face elevated risks of developing triple-negative breast cancers, which are often aggressive and do not respond to hormone therapy or targeted therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

ConclusionThe results of this study indicated that HIIT has positive impacts on the cardiorespiratory fitness and inflammatory cytokines in the breast cancer patients undergoing hormone therapy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 August 2019Source: Annals of Physical and Rehabilitation MedicineAuthor(s): Shaban Alizadeh, Amin Isanejad, Sanambar Sadighi, Solmaz Khalighfard, Ali Mohammad AlizadehAbstractBackground: The role of microRNAs (miRs) in hormone therapy (HT) is of keen interest in developing biomarkers and treatments for individuals with breast cancer. Although miRs are often moderate regulators under homeostatic conditions, their function is changed more in response to physical activity.Objective: This single-blind randomized trial aimed to explore the effect of high-intensity interval training (HIIT) on...
Source: Annals of Physical and Rehabilitation Medicine - Category: Rehabilitation Source Type: research
Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We ...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Abstract In order to implement academic detailing, it is extremely important to understand the pharmacological activity of drugs based on their chemical structures. To construct a database for academic detailing, a viewpoint for clinically utilizing the fundamental pharmacological features of a drug is required. These fundamental pharmacological features include chemical characteristics such as chemical structures, physical characteristics such as pharmaceutical formulations for efficient drug delivery to target organs, and a pharmacological viewpoint, which is a mechanism by which a drug is determined to be effec...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research
CONCLUSION: Collectively, these findings suggest that while FGFR1 amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, TORC1 inhibitors might have a unique therapeutic role in the treatment of patients with ER+/FGFR1+ MBC. PMID: 31371343 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This article investigates how Black South Africans residing in Soweto, a township of Johannesburg, perceive and experience breast and prostate cancers amidst multiple, concurrent medical conditions. We used convenience sampling to recruit 80 study participants already enrolled in longitudinal studies of breast and prostate cancers at a tertiary hospital in Soweto between June and August 2017. This included 50 women diagnosed with breast cancer and 30 men diagnosed with prostate cancer; three-quarters of the sample had two or more comorbidities, including HIV, hypertension, diabetes, anxiety, and others. Many described sick...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
Estrogen receptor 1 (ESR1) mutations have been identified in hormone therapy resistant breast cancer and primary endometrial cancer. Analyses in breast cancer suggests that mutant ESR1 exhibits estrogen independent activity. In endometrial cancer, ESR1 mutations are associated with worse outcomes and less obesity, however experimental investigation of these mutations has not been performed. Using a unique CRISPR/Cas9 strategy, we introduced the D538G mutation, a common endometrial cancer mutation that alters the ligand binding domain of ESR1, while epitope tagging the endogenous locus. We discovered estrogen-independent mu...
Source: Genome Research - Category: Genetics & Stem Cells Authors: Tags: RESEARCH Source Type: research
The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on literature review, about osteoporosis prevention and treatment in these patients. The following scientific societies contributed to the work : Société Française de Rhumatologie (SFR), Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO), Groupe Européen d'Etudes des Métastases Osseuses (GEMO), Association Francophone pour les Soins Oncologiques de Support (AFSOS), Société Française de Sénologie et de Pathologie M...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Damu Tang Breast cancer stem cells (BCSC) play critical roles in the acquisition of resistance to endocrine therapy in estrogen receptor (ER)-positive (ER + ve) breast cancer (BC). The resistance results from complex alterations involving ER, growth factor receptors, NOTCH, Wnt/β-catenin, hedgehog, YAP/TAZ, and the tumor microenvironment. These mechanisms are likely converged on regulating BCSCs, which then drive the development of endocrine therapy resistance. In this regard, hormone therapies enrich BCSCs in ER + ve BCs under both pre-clinical and clinical settings along with upregulation of the core compo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
yong-Huey Lai Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acet...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | International Medicine & Public Health | Study | Women